Skip to main content

Advertisement

Table 1 Unadjusted hazard ratios for death in relation to stromal ER and PR expression, allover and stratified by KRAS mutation status and sex, respectively

From: Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma

 AllKRAS wild-typeKRAS mutated 
n (events)HR (95% CI)n (events)HR (95% CI)n (events)HR (95% CI)Pinteraction
ER status
 All
  ER-118 (93)1.0040 (27)1.0034 (28)1.000.694
  ER+48 (39)0.97 (0.67–1.41)13 (10)1.14 (0.55–2.37)12 (11)0.93 (0.46–1.88)0.757a
  p 0.865 0.721 0.841 
 Women
  ER-49 (35)1.0017 (10)1.0014 (10)1.000.874
  ER+35 (26)1.05 (0.63–1.74)8 (5)1.09 (0.37–3.22)8 (7)1.35 (0.50–3.65)0.947a
  p 0.864 0.870 0.548 
 Men
  ER-69 (58)1.0023 (17)1.0020 (18)1.000.387
  ER+13 (13)1.12 (0.61–2.05)5 (5)1.30 (0.47–3.59)4 (4)0.63 (0.21–1.92)0.516a
  p 0.723 0.613 0.420 
PR status
 All
  PR-111 (86)1.0038 (24)1.0029 (26)1.000.026
  PR+49 (43)1.25 (0.87–1.81)12 (11)1.94 (0.94–3.98)17 (14)0.66 (0.34–1.27)0.037a
  p 0.234 0.071 0.216 
 Women
  PR-52 (36)1.0018 (9)1.0012 (11)1.000.002
  PR+28 (24)1.35 (0.80–2.27)6 (6)2.85 (1.01–8.09)9 (6)0.030 (0.11–0.85)0.004a
  p 0.257 0.048 0.024b 
 Men
  PR-59 (50)1.0020 (15)1.0017 (15)1.000.678
  PR+21 (19)1.23 (0.72–2.09)6 (5)1.32 (0.47–3.70)8 (8)1.70 (0.71–4.07)0.785a
  p 0.452 0.592 0.234 
  1. aInteraction analysis including adjustment for morphological type (I-type/PB-type)
  2. bHazard ratio adjusted for morphological type 0.28 (0.10–0.80) in women